Javier J. Rodriguez's Insider Trades & SAST Disclosures
Javier J. Rodriguez's most recent trade in Gilead Sciences, Inc. was a trade of 6,809 Non-qualified Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 7, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Javier J. Rodriguez.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Javier J. Rodriguez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2025 | 6,809 | 6,809 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Javier J. Rodriguez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2025 | 1,516 | 12,218 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2025 | 52,106 | 52,106 | - | - | Stock Appreciation Rights | |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2025 | 18,822 | 894,080 (0%) | 0% | 0 | Common Stock | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 34 | 1,591 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 34 | 387 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 31 | 229 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 31 | 1,557 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2024 | 562 | 5,064 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2024 | 562 | 24,853 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2024 | 521 | 24,291 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2024 | 521 | 2,606 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Sale of securities on an exchange or to another person at price $ 0.35 per share. | 14 Dec 2024 | 220 | 24,423 (0%) | 0% | 0.4 | 78 | Common Stock |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Sale of securities on an exchange or to another person at price $ 0.36 per share. | 14 Dec 2024 | 210 | 24,643 (0%) | 0% | 0.4 | 75 | Common Stock |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2024 | 37,423 | 875,258 (0%) | 0% | 0 | Common Stock | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2024 | 21,250 | 30,633 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Sale of securities on an exchange or to another person at price $ 0.55 per share. | 17 Sep 2024 | 6,863 | 23,770 (0%) | 0% | 0.6 | 3,775 | Common Stock |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 563 | 9,478 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 563 | 5,625 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 521 | 8,915 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 521 | 3,127 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Sale of securities on an exchange or to another person at price $ 0.69 per share. | 14 Sep 2024 | 345 | 9,133 (0%) | 0% | 0.7 | 238 | Common Stock |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 165.05 per share. | 13 Sep 2024 | 50,000 | 837,835 (0%) | 0% | 165.1 | 8,252,515 | Common Stock |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 162.85 per share. | 13 Sep 2024 | 9,881 | 887,835 (0%) | 0% | 162.9 | 1,609,122 | Common Stock |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 155.93 per share. | 26 Aug 2024 | 32,176 | 905,659 (0%) | 0% | 155.9 | 5,017,303 | Common Stock |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 155.93 per share. | 26 Aug 2024 | 7,943 | 897,716 (0%) | 0% | 155.9 | 1,238,589 | Common Stock |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.80 per share. | 20 Aug 2024 | 750,000 | 1,453,929 (1%) | 0% | 67.8 | 50,850,000 | Common Stock |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2024 | 750,000 | 0 | - | - | Stock Appreciation Rights | |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 152.17 per share. | 20 Aug 2024 | 334,166 | 1,119,763 (0%) | 0% | 152.2 | 50,850,040 | Common Stock |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 152.17 per share. | 20 Aug 2024 | 181,928 | 937,835 (0%) | 0% | 152.2 | 27,683,984 | Common Stock |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 1,875 | 1,875 | - | - | Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 625 | 625 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 562 | 6,188 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 562 | 8,755 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 521 | 8,193 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 521 | 3,648 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Sale of securities on an exchange or to another person at price $ 1.26 per share. | 14 Jun 2024 | 361 | 8,394 (0%) | 0% | 1.3 | 456 | Common Stock |
| Gilead Sciences, Inc. | Javier J. Rodriguez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 12,648 | 12,648 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Javier J. Rodriguez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 2,310 | 10,702 (0%) | 0% | 0 | Common Stock | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 2,250 | 6,750 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 2,250 | 8,684 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Sale of securities on an exchange or to another person at price $ 2.64 per share. | 14 Mar 2024 | 1,012 | 7,672 (0%) | 0% | 2.6 | 2,667 | Common Stock |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 521 | 4,169 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 521 | 6,434 (0%) | 0% | - | Common Stock | |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.80 per share. | 06 Mar 2024 | 750,000 | 1,244,480 (0%) | 0% | 67.8 | 50,850,000 | Common Stock |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 750,000 | 750,000 | - | - | Stock Appreciation Rights | |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 134.65 per share. | 06 Mar 2024 | 377,646 | 866,834 (0%) | 0% | 134.7 | 50,850,034 | Common Stock |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 134.65 per share. | 06 Mar 2024 | 162,905 | 703,929 (0%) | 0% | 134.6 | 21,935,158 | Common Stock |
| DaVita Inc | J. Javier Rodriguez | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 450,000 | 1,550,000 | - | - | Stock Appreciation Rights | |
| DaVita Inc | Rodriguez Javier J. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.80 per share. | 26 Feb 2024 | 450,000 | 889,002 (0%) | 0% | 67.8 | 30,510,000 | Common Stock |
| DaVita Inc | Javier Rodriguez J. | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 125.26 per share. | 26 Feb 2024 | 243,574 | 645,428 (0%) | 0% | 125.3 | 30,510,079 | Common Stock |
| DaVita Inc | Javier Rodriguez J. | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 125.26 per share. | 26 Feb 2024 | 89,128 | 556,300 (0%) | 0% | 125.3 | 11,164,173 | Common Stock |
| DaVita Inc | Rodriguez J. Javier | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 126.11 per share. | 26 Feb 2024 | 67,603 | 488,697 (0%) | 0% | 126.1 | 8,525,130 | Common Stock |
| DaVita Inc | Javier Rodriguez J. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.80 per share. | 26 Feb 2024 | 50,000 | 531,300 (0%) | 0% | 67.8 | 3,390,000 | Common Stock |
| DaVita Inc | Javier Rodriguez J. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 50,000 | 1,500,000 | - | - | Stock Appreciation Rights | |
| DaVita Inc | Rodriguez J. Javier | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 127.60 per share. | 26 Feb 2024 | 26,568 | 504,732 (0%) | 0% | 127.6 | 3,390,077 | Common Stock |
| DaVita Inc | Javier Rodriguez J. | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 127.60 per share. | 26 Feb 2024 | 10,252 | 494,480 (0%) | 0% | 127.6 | 1,308,155 | Common Stock |
| DaVita Inc | J. Rodriguez Javier | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 126.87 per share. | 26 Feb 2024 | 7,397 | 481,300 (0%) | 0% | 126.9 | 938,467 | Common Stock |
| DaVita Inc | Javier Rodriguez J. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 500,000 | 2,000,000 | - | - | Stock Appreciation Rights | |
| DaVita Inc | J. Javier Rodriguez | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.80 per share. | 14 Dec 2023 | 500,000 | 833,299 (0%) | 0% | 67.8 | 33,900,000 | Common Stock |
| DaVita Inc | Javier Rodriguez J. | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 108.80 per share. | 14 Dec 2023 | 311,581 | 521,718 (0%) | 0% | 108.8 | 33,900,013 | Common Stock |
| DaVita Inc | Rodriguez J. Javier | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 108.80 per share. | 14 Dec 2023 | 82,716 | 439,002 (0%) | 0% | 108.8 | 8,999,501 | Common Stock |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 521 | 5,913 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 521 | 4,690 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2023 | 521 | 5,392 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2023 | 521 | 5,211 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2023 | 521 | 5,732 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2023 | 521 | 4,871 (0%) | 0% | - | Common Stock | |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 96.86 per share. | 15 May 2023 | 25,805 | 333,299 (0%) | 0% | 96.9 | 2,499,472 | Common Stock |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 96.86 per share. | 15 May 2023 | 15,298 | 359,104 (0%) | 0% | 96.9 | 1,481,764 | Common Stock |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2023 | 5,000 | 0 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2023 | 5,000 | 6,135 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Sale of securities on an exchange or to another person at price $ 27.32 per share. | 14 May 2023 | 1,785 | 4,350 (0%) | 0% | 27.3 | 48,765 | Common Stock |
| Gilead Sciences, Inc. | Javier J. Rodriguez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 10,173 | 10,173 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Javier J. Rodriguez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 1,887 | 8,392 (0%) | 0% | 0 | Common Stock | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 32,000 | 32,000 | - | - | Stock Option (Right to Buy) | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 9,000 | 9,000 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2023 | 2,084 | 6,253 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2023 | 2,084 | 2,084 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Sale of securities on an exchange or to another person at price $ 19.63 per share. | 14 Mar 2023 | 950 | 1,135 (0%) | 0% | 19.6 | 18,644 | Common Stock |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jun 2022 | 79,909 | 0 | - | - | Stock Appreciation Rights | |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 65.48 per share. | 06 Jun 2022 | 79,909 | 381,059 (0%) | 0% | 65.5 | 5,232,441 | Common Stock |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 96.70 per share. | 06 Jun 2022 | 54,111 | 326,948 (0%) | 0% | 96.7 | 5,232,534 | Common Stock |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 96.70 per share. | 06 Jun 2022 | 11,326 | 315,622 (0%) | 0% | 96.7 | 1,095,224 | Common Stock |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2022 | 5,000 | 5,000 | - | - | Restricted Stock Units | |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 100.05 per share. | 12 May 2022 | 29,076 | 320,321 (0%) | 0% | 100.1 | 2,909,054 | Common Stock |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 24,890 | 379,311 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 100.05 per share. | 12 May 2022 | 17,233 | 362,078 (0%) | 0% | 100.1 | 1,724,162 | Common Stock |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 100.05 per share. | 12 May 2022 | 15,298 | 301,150 (0%) | 0% | 100.1 | 1,530,565 | Common Stock |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 100.05 per share. | 12 May 2022 | 12,681 | 349,397 (0%) | 0% | 100.0 | 1,268,734 | Common Stock |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 100.05 per share. | 12 May 2022 | 3,873 | 316,448 (0%) | 0% | 100.1 | 387,494 | Common Stock |
| Gilead Sciences, Inc. | Javier J. Rodriguez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 15,851 | 15,851 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Javier J. Rodriguez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 2,444 | 6,505 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Javier J. Rodriguez | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 2,223 | 4,061 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Javier J. Rodriguez | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 2,223 | 0 | - | - | Restricted Stock Unit | |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Apr 2022 | 66,230 | 340,057 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Apr 2022 | 28,884 | 273,827 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Javier J. Rodriguez | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Apr 2022 | 14,364 | 354,421 (0%) | 0% | 0 | Common Stock | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2022 | 33,350 | 33,350 | - | - | Stock Option (Right to Buy) | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2022 | 8,337 | 8,337 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Javier Rodriguez | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges